In an attempt to determine whether iASPP expression levels are associated with genetic risk profiles, all patients with newly diagnosed AML were classified into three risk groups according to the ELN 2017 predictive risk stratification score (which was the current risk score at the time the patients were treated) [8]. Here, PPP1R13L is linked to acute myeloid leukemia.